Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer

References

• Ugai T, Sasamoto N, Lee HY, Ando M, Song M, Tamimi RM, Kawachi I, Campbell PT, Giovannucci EL, Weiderpass E, et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol. 2022;19:656–8. doi:10.1038/s41571-022-00672-8.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Enot DP, Pietrocola F, Zitvogel L, Kroemer G. Impact of pattern recognition receptors on the prognosis of breast cancer patients undergoing adjuvant chemotherapy. Cancer Res. 2016;76:3122–3126. doi:10.1158/0008-5472.CAN-16-0294.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350:972–978. doi:10.1126/science.aad0779.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Ma Y, Baracco EE, Zitvogel L, Kroemer G. Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: formyl peptide receptor-1. Oncoimmunology. 2016;5:e1118600. doi:10.1080/2162402X.2015.1118600.
   PubMed Web of Science ®Google Scholar
• Chiang SF, Huang KC, Chen WT, Chen TW, Ke TW, Chao KSC. Polymorphism of formyl peptide receptor 1 (FPR1) reduces the therapeutic efficiency and antitumor immunity after neoadjuvant chemoradiotherapy (CCRT) treatment in locally advanced rectal cancer. Cancer Immunol Immunother. 2021;70:2937–2950. doi:10.1007/s00262-021-02894-8.
   PubMed Web of Science ®Google Scholar
• Chiang SF, Huang KC, Chen WT, Chen TW, Ke TW, Chao KSC. An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1). Oncoimmunology. 2021;10:1926074. doi:10.1080/2162402X.2021.1926074.
   PubMed Web of Science ®Google Scholar
• Baracco EE, Pietrocola F, Buque A, Bloy N, Senovilla L, Zitvogel L, Vacchelli E, Kroemer G. Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. Oncoimmunology. 2016;5:e1139275. doi:10.1080/2162402X.2016.1139275.
   PubMed Web of Science ®Google Scholar
• Le Naour J, Liu P, Zhao L, Adjemian S, Sztupinszki Z, Taieb J, Mulot C, Silvin A, Dutertre C-A, Ginhoux F, et al. A TLR3 ligand reestablishes chemotherapeutic responses in the context of FPR1deficiency. Cancer Discov. 2021;11:408–423. doi:10.1158/2159-8290.CD-20-0465.
   PubMed Web of Science ®Google Scholar
• Biselli E, Agliari E, Barra A, Bertani FR, Gerardino A, De Ninno A, Mencattini A, Di Giuseppe D, Mattei F, Schiavoni G, et al. Organs on chip approach: a tool to evaluate cancer -immune cells interactions. Sci Rep. 2017;7:12737. doi:10.1038/s41598-017-13070-3.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23:487–500. doi:10.1038/s41590-022-01132-2.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860–875. doi:10.1038/nrc3380.
   PubMed Web of Science ®Google Scholar
• Buque A, Bloy N, Perez-Lanzon M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A, et al. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nat Commun. 2020;11:3819. doi:10.1038/s41467-020-17644-0.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21:1128–1138. doi:10.1038/nm.3944.
   PubMed Web of Science ®Google Scholar
• Sztupinszki Z, Le Naour J, Vacchelli E, Laurent-Puig P, Delaloge S, Szallasi Z, Kroemer G. A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. Oncoimmunology. 2021;10:1859064. doi:10.1080/2162402X.2020.1859064.
   PubMed Web of Science ®Google Scholar
• Delrieu L, Jacquet E, Segura-Ferlay C, Blanc E, Febvey-Combes O, Friedenreich C, Romieu G, Jacot W, Rios M, Heudel P-E, et al. Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer. Sci Rep. 2020;10:10757. doi:10.1038/s41598-020-67431-6.
   PubMed Web of Science ®Google Scholar
• Marinovich ML, Bernardi D, Macaskill P, Ventriglia A, Sabatino V, Houssami N. Agreement between digital breast tomosynthesis and pathologic tumour size for staging breast cancer, and comparison with standard mammography. Breast. 2019;43:59–66. doi:10.1016/j.breast.2018.11.001.
   PubMed Web of Science ®Google Scholar
• Wick G, Jansen-Durr P, Berger P, Blasko I, Grubeck-Loebenstein B. Diseases of aging. Vaccine. 2000;18:1567–1583. doi:10.1016/S0264-410X(99)00489-2.
   PubMed Web of Science ®Google Scholar
• Dean M, Carrington M, O’brien SJ. Balanced polymorphism selected by genetic versus infectious human disease. Annu Rev Genomics Hum Genet. 2002;3:263–292. doi:10.1146/annurev.genom.3.022502.103149.
   PubMed Web of Science ®Google Scholar
• Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, Izagirre N, Syafruddin D, Kibiki G, Cristea T, Hijmans A, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A. 2007;104:16645–16650. doi:10.1073/pnas.0704828104.
   PubMed Web of Science ®Google Scholar
• Liu M, Chen K, Yoshimura T, Liu Y, Gong W, Wang A, Gao J-L, Murphy PM, Wang JM. Formylpeptide receptors are critical for rapid neutrophil mobilization in host defense against Listeria monocytogenes. Sci Rep. 2012;2:786. doi:10.1038/srep00786.
   PubMed Web of Science ®Google Scholar
• Cho JS, Guo Y, Ramos RI, Hebroni F, Plaisier SB, Xuan C, Granick JL, Matsushima H, Takashima A, Iwakura Y, et al. Neutrophil-derived IL-1β is sufficient for abscess formation in immunity against staphylococcus aureus inmice. PLoS Pathog. 2012;8:e1003047. doi:10.1371/journal.ppat.1003047.
   PubMed Web of Science ®Google Scholar
• Oldekamp S, Pscheidl S, Kress E, Soehnlein O, Jansen S, Pufe T, Wang JM, Tauber SC, Brandenburg L-O. Lack of formyl peptide receptor 1 and 2 leads to more severe inflammation and higher mortality in mice with of pneumococcal meningitis. Immunology. 2014;143:447–461. doi:10.1111/imm.12324.
   PubMed Web of Science ®Google Scholar
• Zhang M, Gao JL, Chen K, Yoshimura T, Liang W, Gong W, Li X, Huang J, McDermott DH, Murphy PM, et al. A critical role of formyl peptide receptors in host defense against escherichia coli. J Immunol. 2020;204:2464–2473. doi:10.4049/jimmunol.1900430.
   PubMed Web of Science ®Google Scholar
• Osei-Owusu P, Charlton TM, Kim HK, Missiakas D, Schneewind O. FPR1 is the plague receptor on host immune cells. Nature. 2019;574:57–62. doi:10.1038/s41586-019-1570-z.
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Le Naour J, Kroemer G. The ambiguous role of FPR1 in immunity and inflammation. Oncoimmunology. 2020;9:1760061. doi:10.1080/2162402X.2020.1760061.
   PubMed Web of Science ®Google Scholar
• Liu M, Chen K, Yoshimura T, Liu Y, Gong W, Le Y, Gao J-L, Zhao J, Wang JM, Wang A, et al. Formylpeptide receptors mediate rapid neutrophil mobilization to accelerate wound healing. PLoS One. 2014;9:e90613. doi:10.1371/journal.pone.0090613.
   PubMed Web of Science ®Google Scholar
• Giebeler A, Streetz KL, Soehnlein O, Neumann U, Wang JM, Brandenburg LO, Mukhopadhyay P. Deficiency of formyl peptide receptor 1 and 2 is associated with increased inflammation and enhanced liver injury after LPS-stimulation. PLoS One. 2014;9:e100522. doi:10.1371/journal.pone.0100522.
   PubMed Web of Science ®Google Scholar
• Grommes J, Drechsler M, Soehnlein O. CCR5 and FPR1 mediate neutrophil recruitment in endotoxin-induced lung injury. J Innate Immun. 2014;6:111–116. doi:10.1159/000353229.
   PubMed Web of Science ®Google Scholar
• Cardini S, Dalli J, Fineschi S, Perretti M, Lungarella G, Lucattelli M. Genetic ablation of the fpr1 gene confers protection from smoking-induced lung emphysema in mice. Am J Respir Cell Mol Biol. 2012;47:332–339. doi:10.1165/rcmb.2012-0036OC.
   PubMed Web of Science ®Google Scholar
• Gao L, Zeng N, Yuan Z, Wang T, Chen L, Yang D, Xu D, Wan C, Wen F, Shen Y. Knockout of formyl peptide receptor-1 attenuates cigarette smoke–induced airway inflammation in mice. Front Pharmacol. 2021;12:632225. doi:10.3389/fphar.2021.632225.
   PubMed Web of Science ®Google Scholar
• Dorward DA, Lucas CD, Doherty MK, Chapman GB, Scholefield EJ, Conway Morris A, Felton JM, Kipari T, Humphries DC, Robb CT, et al. Novel role for endogenous mitochondrial formylated peptide-driven formyl peptide receptor 1 signalling in acute respiratory distress syndrome. Thorax. 2017;72:928–936. doi:10.1136/thoraxjnl-2017-210030.
   PubMed Web of Science ®Google Scholar
• Leslie J, Millar BJ, Del Carpio Pons A, Burgoyne RA, Frost JD, Barksby BS, Luli S, Scott J, Simpson AJ, Gauldie J, et al. FPR-1 is an important regulator of neutrophil recruitment and a tissue-specific driver of pulmonary fibrosis. JCI Insight. 2020;5. doi:10.1172/jci.insight.125937.
   PubMed Web of Science ®Google Scholar
• Scozzi D, Ibrahim M, Liao F, Lin X, Hsiao HM, Hachem R, Tague LK, Ricci A, Kulkarni HS, Huang HJ, et al. Mitochondrial damage–associated molecular patterns released by lung transplants are associated with primary graft dysfunction. Am J Transplant. 2019;19:1464–1477. doi:10.1111/ajt.15232.
   PubMed Web of Science ®Google Scholar
• D’amico R, Fusco R, Cordaro M, Siracusa R, Peritore AF, Gugliandolo E, Crupi R, Scuto M, Cuzzocrea S, Di Paola R, et al. Modulation of NLRP3 inflammasome through formyl peptide receptor 1 (Fpr-1) pathway as a new therapeutic target in bronchiolitis obliterans syndrome. Int J Mol Sci. 2020;21. doi:10.3390/ijms21062144.
   Web of Science ®Google Scholar
• Fusco R, D’amico R, Cordaro M, Gugliandolo E, Siracusa R, Peritore AF, Crupi R, Impellizzeri D, Cuzzocrea S, Di Paola R. Absence of formyl peptide receptor 1 causes endometriotic lesion regression in a mouse model of surgically-induced endometriosis. Oncotarget. 2018;9:31355–31366. doi:10.18632/oncotarget.25823.
   PubMedGoogle Scholar
• Bihler K, Kress E, Esser S, Nyamoya S, Tauber SC, Clarner T, Stope MB, Pufe T, Brandenburg L-O. Formyl peptide Receptor 1-mediated glial cell activation in a mouse model of cuprizone-induced demyelination. J Mol Neurosci. 2017;62:232–243. doi:10.1007/s12031-017-0924-y.
   PubMed Web of Science ®Google Scholar
• Di Paola R, Fusco R, Gugliandolo E, D’amico R, Cordaro M, Impellizzeri D, Perretti M, Cuzzocrea S. Formyl peptide receptor 1 signalling promotes experimental colitis in mice. Pharmacol Res. 2019;141:591–601. doi:10.1016/j.phrs.2019.01.041.
   PubMed Web of Science ®Google Scholar
• Wollam J, Riopel M, Xu YJ, Johnson AMF, Ofrecio JM, Ying W, El Ouarrat D, Chan LS, Han AW, Mahmood NA, et al. Microbiota-produced N-Formyl peptide fMLF promotes obesity-induced glucose intolerance. Diabetes. 2019;68:1415–1426. doi:10.2337/db18-1307.
   PubMed Web of Science ®Google Scholar
• Gao JL, Weaver JD, Tuo J, Wang LQ, Siwicki M, Despres D, Lizak M, Schneider EH, Kovacs W, Maminishkis A, et al. Leukocyte chemotactic receptor Fpr1 protects against aging-related posterior subcapsular cataract formation. Faseb J. 2021;35:e21315. doi:10.1096/fj.202002135R.
   PubMed Web of Science ®Google Scholar
• Fusco R, Gugliandolo E, Siracusa R, Scuto M, Cordaro M, D’amico R, Evangelista M, Peli A, Peritore AF, Impellizzeri D, et al. Formyl peptide receptor 1 signaling in acute inflammation and neural differentiation induced by traumatic brain injury. Biology (Basel). 2020;9. doi:10.3390/biology9090238.
   Google Scholar
• Li Z, Li Y, Han J, Zhu Z, Li M, Liu Q, Wang Y, Shi F-D. Formyl peptide receptor 1 signaling potentiates inflammatory brain injury. Sci Transl Med. 2021;13. doi:10.1126/scitranslmed.abe9890.
   Web of Science ®Google Scholar
• Duvvuri B, Baddour AA, Deane KD, Feser ML, Nelson JL, Demoruelle MK, Lood C. Mitochondrial N-formyl methionine peptides associate with disease activity as well as contribute to neutrophil activation in patients with rheumatoid arthritis. J Autoimmun. 2021;119:102630. doi:10.1016/j.jaut.2021.102630.
   PubMed Web of Science ®Google Scholar
• Kuley R, Stultz RD, Duvvuri B, Wang T, Fritzler MJ, Hesselstrand R, Nelson JL, Lood C. N-Formyl methionine peptide-mediated neutrophil activation in systemic sclerosis. Front Immunol. 2021;12:785275. doi:10.3389/fimmu.2021.785275.
   PubMed Web of Science ®Google Scholar
• Michailidou D, Duvvuri B, Kuley R, Cuthbertson D, Grayson PC, Khalidi NA, Koening CL, Langford CA, McAlear CA, Moreland LW, et al. Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. Arthritis Res Ther. 2022;24:160. doi:10.1186/s13075-022-02849-z.
   PubMed Web of Science ®Google Scholar
• Kwon WY, Suh GJ, Jung YS, Park SM, Oh S, Kim SH, Lee AR, Kim JY, Kim H, Kim KA, et al. Circulating mitochondrial N-formyl peptides contribute to secondary nosocomial infection in patients with septic shock. Proc Natl Acad Sci U S A. pp.118. 2021. doi:10.1073/pnas.2018538118
   Web of Science ®Google Scholar
• Tamimi RM, Colditz GA, Hazra A, Baer HJ, Hankinson SE, Rosner B, Marotti J, Connolly JL, Schnitt SJ, Collins LC. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;131:159–167. doi:10.1007/s10549-011-1702-0.
   PubMed Web of Science ®Google Scholar
• Crispo A, Augustin LS, Grimaldi M, Nocerino F, Giudice A, Cavalcanti E, Di Bonito M, Botti G, De Laurentiis M, Rinaldo M, et al. Risk differences between prediabetes and diabetes according to breast cancer molecular subtypes. J Cell Physiol. 2017;232:1144–1150. doi:10.1002/jcp.25579.
   PubMed Web of Science ®Google Scholar
• Yang X, Eriksson M, Czene K, Lee A, Leslie G, Lush M, Wang J, Dennis J, Dorling L, Carvalho S, et al. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study. J Med Genet. 2022;59:1196–1205. doi:10.1136/jmg-2022-108806.
   PubMed Web of Science ®Google Scholar
• Pashayan N, Antoniou AC, Lee A, Wolfson M, Chiquette J, Eloy L, Eisen A, Stockley TL, Nabi H, Brooks JD, et al. Should age-dependent absolute risk thresholds be used for risk stratification in risk-stratified breast cancer screening? J Pers Med. pp.11. 2021. doi:10.3390/jpm11090916
   PubMed Web of Science ®Google Scholar
• Graffeo R, Rana HQ, Conforti F, Bonanni B, Cardoso MJ, Paluch-Shimon S, Pagani O, Goldhirsch A, Partridge AH, Lambertini M, et al. Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: aTM, CHEK2, BARD1 and RAD51D. Breast. 2022;65:32–40. doi:10.1016/j.breast.2022.06.003.
   PubMedGoogle Scholar
• Hughes E, Wagner S, Pruss D, Bernhisel R, Probst B, Abkevich V, Simmons T, Hullinger B, Judkins T, Rosenthal E, et al. Development and validation of a breast cancer polygenic risk score on the basis of genetic ancestry composition. JCO Precis Oncol. 2022;6:e2200084. doi:10.1200/PO.22.00084.
   PubMed Web of Science ®Google Scholar